# Shorter and Safer Treatment Regimens for Latent TB

> **NCT06498414** · PHASE2,PHASE3 · RECRUITING · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 1800 (estimated)

## Conditions studied

- Tuberculosis Infection, Latent

## Interventions

- **DRUG:** rifampin standard arm
- **DRUG:** rifampin double dose
- **DRUG:** levofloxacin and rifapentine

## Key facts

- **NCT ID:** NCT06498414
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-10
- **Primary completion:** 2027-04-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 1800 (ESTIMATED)
- **Last updated:** 2026-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06498414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06498414, "Shorter and Safer Treatment Regimens for Latent TB". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT06498414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*